Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others.
We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
CEO Spotlight: William Hartman recently joined Donald Baillargeon on MoneyTV for an in-depth update on Halberd’s progress over the last 3 years.
Halberd Corporation Fact Sheet
A brief review of some of Halberd’s significant accomplishments and recent developments.
PROPRIETARY SEQUENTIAL DIALYSIS TECHNIQUE
A methodology that physically removes the pathophysiologic basis of the disease
The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.
- Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
- Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional “Additive” therapy (adding chemicals to the body).
- Targets Covid-19 and similar viral diseases initially, with future efforts to develop treatments for Alzheimer’s Disease, PTSD/Traumatic Brain Injury, and cancer.
Press releases and updates on our medical breakthroughs.